The aim of this study was to evaluate the reliability and quality of information provided by artificial intelligence chatbots regarding the diagnosis, preventive methods, and treatment of contrast-associated acute kidney injury, while also discussing their benefits and drawbacks. The most frequently asked questions regarding contrast-associated acute kidney injury on Google Trends between January 2022 and January 2024 were posed to four artificial intelligence chatbots: ChatGPT, Gemini, Copilot, and Perplexity. The responses were evaluated based on the DISCERN score, the Patient Education Materials Assessment Tool for Printable Materials score, the Web Resource Rating scale, the Coleman-Liau index, and a Likert scale. As per the DISCERN score, the quality of information provided by Perplexity received a rating of "good", while the quality of information acquired by ChatGPT, Gemini, and Copilot was scored as "average." Based on the Coleman-Liau index, the readability of the responses was greater than 11 for all artificial intelligence chatbots, suggesting a high level of complexity requiring a university-level education. Similarly, the understandability and applicability scores on the Patient Education Materials Assessment Tool for Printable Materials and the Web Resource Rating scale were low for all artificial intelligence programs. In consideration of the Likert score, all artificial intelligence chatbots received favorable ratings. While patients increasingly utilize artificial intelligence chatbots to acquire information about contrast-associated acute kidney injury, the readability and understandability of the information provided may be low.

The aim of this study was to investigate the impact of sarcopenia on prognosis in patients with gastric cancer in order to explore the relationship between sarcopenia and postoperative complications as well as durations of hospital stay and intensive care unit.

Objective: Recommendations for the treatment of cytokine release syndrome/macrophage activation syndrome (MAS) associated with coronavirus disease-2019 (COVID-19) are still of poor quality. IL-6 is an important therapeutic target as a main mediator of cytokine storm. The aim of our study was to evaluate the tocilizumab (TCZ) efficacy and factors affecting the therapy outcome. Methods: This retrospective study included 27 patients treated with TCZ for COVID-19-MAS. All patients in this study were treated with TCZ (intravenously, at a dose of 8 mg kg1 ) in addition to standard therapy. Clinical improvement (survival and decreased oxygen demand) on the 10-14th days and secondary infection rate were assessed. Results: In our 27 treated patients, 14 (51.8%) received TCZ in the intensive care unit (ICU) and seven (25.9%) were need to invasive mechanical ventilation (IMV). Fifteen (55.6%) of these patients revealed a good clinical response (four patients discharge from the ICU and 11 patients who followed-up in nonICU beds showed a decrease in oxygen demand). TCZ was significantly less effective in patients having high Murray lung injury score, low PO2/FiO2 ratio, IMV, and ICU admission (P < .05). Severity of hypoxemia was found as a single independent risk factor in the multivariable analysis (P < .05). Secondary bacterial infections rate was significantly higher in intubated patients (P < .01) or treated in the ICU (P ¼ .01). Conclusion: TCZ was showed limited efficacy for COVID-19-related MAS. The most important predictive indicator for therapy outcome was found as the severity of hypoxemia. In addition, IMV and/or ICU was associated with the poor outcome and high side effect. So, controlled trials are still needed to confirm the indications and timing of TCZ therapy. Cite this article as: Akleylek C, Gür SG, Sever İH, et al. What are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome? Eur J Rheumatol. 2022;9(3):126-131.

Background: This study aimed to evaluate the diagnostic performance of the Kaiser score (KS) on the modified abbreviated breast magnetic resonance imaging (AB-MRI) protocol for characterizing breast lesions by comparing it with full-protocol MRI (FP-MRI), using the histological data as the reference standard. Methods: Breast MRIs detecting histologically verified contrast-enhancing breast lesions were evaluated retrospectively. A modified AB-MRI protocol was created from the standard FP-MRI, which comprised axial fat-suppressed T2-weighted imaging (T2WI), pre-contrast T1-weighted imaging (T1WI), and first, second, and fourth post-contrast phases. Two radiologists reviewed both protocols, recording the KS for each detected lesion. Sensitivity, specificity, and positive and negative predictive values, as well as accuracy, were calculated for each protocol. Receiver operating characteristic (ROC) analysis was performed to determine the diagnostic performance of the modified AB-MRI compared to the FP-MRI. Results: In total, 154 patients with 158 histopathologically proven lesions (107 malignant, 51 benign) were included. For the diagnostic performance of the KS for modified AB-MRI and FP-MRI, the sensitivity was 96.3% vs. 98.1%, the specificity was 78.4% vs. 74.5%, PPV was 90.4% vs. 89%, NPV was 90.9% vs. 95%, and the diagnostic accuracy was 90.5% vs. 90.5%. The area under the curve (AUC) obtained from the ROC curve analysis was 0.873 and 0.863 for modified AB-MRI and FP-MRI for reader 1, respectively, and 0.859 and 0.878 for modified AB-MRI and FP-MRI for reader 2, respectively, (p < 0.001). Conclusions: Our modified AB-MRI protocol revealed comparable results in terms of the diagnostic value of the KS in characterizing breast lesions compared to FP-MRI and reduced both scanning and interpretation time.

The Importance of Body Fat Composition Evaluated by Computed Tomography and Its Prognostic Significance in Patients with Testicular Cancer - Istanbul Medical Journal